EZH2
Gene Information
- Official Symbol: EZH2
- Official Name: enhancer of zeste 2 polycomb repressive complex 2 subunit
- Aliases and Previous Symbols: N/A
- Entrez ID: 2146
- UniProt: Q15910
- Interactions: BioGRID
- PubMed articles: Open PubMed
- OMIM: Open OMIM
Function Summary
- Entrez Summary: This gene encodes a member of the Polycomb-group (PcG) family. PcG family members form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations. This protein associates with the embryonic ectoderm development protein, the VAV1 oncoprotein, and the X-linked nuclear protein. This protein may play a role in the hematopoietic and central nervous systems. Multiple alternatively splcied transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Feb 2011].
- UniProt Summary: N/A
Pfam Domains GO Terms
Pfam Domains
| SET |
| EZH2 WD-Binding |
GO Terms
| hepatocyte homeostasis |
| response to tetrachloromethane |
| response to trichostatin A |
| cellular response to trichostatin A |
| skeletal muscle satellite cell maintenance involved in skeletal muscle regeneration |
| histone methyltransferase activity (H3-K27 specific) |
| chromatin silencing at telomere |
| histone H3-K27 trimethylation |
| pronucleus |
| primary miRNA binding |
| negative regulation of retinoic acid receptor signaling pathway |
| G1 to G0 transition |
| histone methyltransferase activity |
| histone H3-K27 methylation |
| negative regulation of transcription elongation from RNA polymerase II promoter |
| negative regulation of DNA-templated transcription, elongation |
| muscle hypertrophy in response to stress |
| negative regulation of epidermal cell differentiation |
| cardiac muscle hypertrophy in response to stress |
| cardiac muscle adaptation |
| ESC/E(Z) complex |
| regulation of retinoic acid receptor signaling pathway |
| negative regulation of epidermis development |
| histone-lysine N-methyltransferase activity |
| protein-lysine N-methyltransferase activity |
| protein localization to chromatin |
| striated muscle adaptation |
| cardiac muscle hypertrophy |
| regulation of transcription elongation from RNA polymerase II promoter |
| liver regeneration |
| striated muscle hypertrophy |
| muscle hypertrophy |
| muscle adaptation |
| ribonucleoprotein complex binding |
| RNA polymerase II core promoter sequence-specific DNA binding |
| skeletal muscle tissue regeneration |
| negative regulation of striated muscle cell differentiation |
| negative regulation of G0 to G1 transition |
| negative regulation of epithelial cell differentiation |
| regulation of G0 to G1 transition |
| DNA methylation |
| DNA alkylation |
| positive regulation of cell cycle G1/S phase transition |
| positive regulation of epithelial to mesenchymal transition |
| cerebellar cortex development |
| promoter-specific chromatin binding |
| regulation of DNA-templated transcription, elongation |
| chromosome, telomeric region |
| negative regulation of muscle cell differentiation |
| chromatin organization involved in negative regulation of transcription |
| chromatin silencing |
| regulation of epidermal cell differentiation |
| protein localization to chromosome |
| tissue regeneration |
| DNA methylation or demethylation |
| cellular response to hydrogen peroxide |
| chromatin organization involved in regulation of transcription |
| chromatin DNA binding |
| histone lysine methylation |
| animal organ regeneration |
| positive regulation of dendrite development |
| negative regulation of gene expression, epigenetic |
| hippocampus development |
| regulation of epithelial to mesenchymal transition |
| regulation of epidermis development |
| DNA modification |
| peptidyl-lysine methylation |
| histone methylation |
| positive regulation of cell cycle phase transition |
| regulation of striated muscle cell differentiation |
| cerebellum development |
| negative regulation of G1/S transition of mitotic cell cycle |
| negative regulation of cell cycle G1/S phase transition |
| limbic system development |
| metencephalon development |
| regulation of circadian rhythm |
| regulation of gliogenesis |
| cellular response to antibiotic |
| response to hydrogen peroxide |
| liver development |
| hepaticobiliary system development |
| cellular response to reactive oxygen species |
| protein alkylation |
| protein methylation |
| response to estradiol |
| maintenance of cell number |
| regulation of epithelial cell differentiation |
| regulation of dendrite development |
| regulation of G1/S transition of mitotic cell cycle |
| hindbrain development |
| gene silencing |
| regulation of muscle cell differentiation |
| regeneration |
| negative regulation of DNA-binding transcription factor activity |
| regulation of cell cycle G1/S phase transition |
| pallium development |
| response to reactive oxygen species |
| homeostasis of number of cells |
| negative regulation of mitotic cell cycle phase transition |
| cellular response to toxic substance |
| negative regulation of cell cycle phase transition |
| regulation of gene expression, epigenetic |
| nuclear chromatin |
| cellular response to oxidative stress |
| transcription corepressor activity |
| macromolecule methylation |
| telencephalon development |
| positive regulation of MAP kinase activity |
| rhythmic process |
| positive regulation of neuron projection development |
| positive regulation of cell cycle process |
| muscle system process |
| response to antibiotic |
| negative regulation of mitotic cell cycle |
| methylation |
| peptidyl-lysine modification |
| negative regulation of cell cycle process |
| positive regulation of protein serine/threonine kinase activity |
| regulation of MAP kinase activity |
| histone modification |
| positive regulation of neuron differentiation |
| covalent chromatin modification |
| positive regulation of cell cycle |
| positive regulation of cell projection organization |
| forebrain development |
| response to oxidative stress |
| developmental growth |
| growth |
| chromatin binding |
| cellular response to drug |
| gland development |
| regulation of mitotic cell cycle phase transition |
| positive regulation of GTPase activity |
| regulation of DNA-binding transcription factor activity |
| regulation of cell cycle phase transition |
| positive regulation of neurogenesis |
| wound healing |
| regulation of GTPase activity |
| regulation of neuron projection development |
| RNA polymerase II proximal promoter sequence-specific DNA binding |
| response to toxic substance |
| regulation of protein serine/threonine kinase activity |
| response to inorganic substance |
| positive regulation of protein kinase activity |
| positive regulation of nervous system development |
| positive regulation of cell development |
| cellular response to organic cyclic compound |
| positive regulation of MAPK cascade |
| response to wounding |
| negative regulation of cell cycle |
| positive regulation of kinase activity |
| cellular response to organonitrogen compound |
| regulation of mitotic cell cycle |
| positive regulation of transferase activity |
| regulation of neuron differentiation |
| cellular response to nitrogen compound |
| regulation of plasma membrane bounded cell projection organization |
| chromatin organization |
| regulation of cell projection organization |
| negative regulation of cell differentiation |
| protein localization to organelle |
| brain development |
| DNA metabolic process |
| regulation of cell cycle process |
| regulation of MAPK cascade |
| positive regulation of hydrolase activity |
| head development |
| regulation of protein kinase activity |
| regulation of neurogenesis |
| response to lipid |
| negative regulation of transcription by RNA polymerase II |
| regulation of kinase activity |
| peptidyl-amino acid modification |
| response to hormone |
| positive regulation of cell population proliferation |
| response to organic cyclic compound |
| regulation of nervous system development |
| regulation of cell development |
| negative regulation of developmental process |
| positive regulation of cell differentiation |
| regulation of transferase activity |
| central nervous system development |
| cell cycle process |
| response to organonitrogen compound |
| positive regulation of protein phosphorylation |
| positive regulation of intracellular signal transduction |
| response to drug |
| cellular response to oxygen-containing compound |
| positive regulation of phosphorylation |
| chromosome organization |
| response to nitrogen compound |
| positive regulation of phosphorus metabolic process |
| positive regulation of phosphate metabolic process |
| negative regulation of molecular function |
| regulation of cell cycle |
| negative regulation of transcription, DNA-templated |
| positive regulation of cellular component organization |
| cellular response to endogenous stimulus |
| positive regulation of protein modification process |
| negative regulation of nucleic acid-templated transcription |
| negative regulation of RNA biosynthetic process |
| negative regulation of signal transduction |
| regulation of hydrolase activity |
| negative regulation of RNA metabolic process |
| cell cycle |
| negative regulation of cell communication |
| negative regulation of signaling |
| positive regulation of developmental process |
| negative regulation of cellular macromolecule biosynthetic process |
| positive regulation of catalytic activity |
| negative regulation of nucleobase-containing compound metabolic process |
| regulation of protein phosphorylation |
| DNA binding |
| negative regulation of macromolecule biosynthetic process |
| response to endogenous stimulus |
| negative regulation of cellular biosynthetic process |
| generation of neurons |
| negative regulation of biosynthetic process |
| response to oxygen-containing compound |
| DNA-binding transcription factor activity, RNA polymerase II-specific |
| cellular protein localization |
| regulation of phosphorylation |
| cellular macromolecule localization |
| positive regulation of cellular protein metabolic process |
| regulation of cell population proliferation |
| negative regulation of response to stimulus |
| neurogenesis |
| homeostatic process |
| positive regulation of signal transduction |
| cellular response to stress |
| positive regulation of protein metabolic process |
| negative regulation of gene expression |
| positive regulation of multicellular organismal process |
| tissue development |
| positive regulation of molecular function |
| regulation of phosphate metabolic process |
| regulation of phosphorus metabolic process |
| regulation of cell differentiation |
| positive regulation of cell communication |
| positive regulation of signaling |
| regulation of intracellular signal transduction |
| regulation of protein modification process |
| system process |
CRISPR Data
Compound Hit Most Correlated Genes in Chemogenomics Tissues where Essential in the Avana Dataset (DepMap 20Q1)
Compound Hit
Tissues where Essential in the Avana Dataset (DepMap 20Q1)
Global Fraction of Cell Lines Where Essential: 0/726
| Tissue | Fraction Of Cell Lines Where Essential |
|---|---|
| 1290807.0 | 0/1 |
| 909776.0 | 0/1 |
| bile duct | 0/28 |
| blood | 0/28 |
| bone | 0/25 |
| breast | 0/33 |
| central nervous system | 0/56 |
| cervix | 0/4 |
| colorectal | 0/17 |
| esophagus | 0/13 |
| fibroblast | 0/1 |
| gastric | 0/15 |
| kidney | 0/21 |
| liver | 0/20 |
| lung | 0/75 |
| lymphocyte | 0/14 |
| ovary | 0/26 |
| pancreas | 0/24 |
| peripheral nervous system | 0/16 |
| plasma cell | 0/15 |
| prostate | 0/1 |
| skin | 0/24 |
| soft tissue | 0/7 |
| thyroid | 0/2 |
| upper aerodigestive | 0/22 |
| urinary tract | 0/29 |
| uterus | 0/5 |
Essentiality in NALM6
- Essentiality Rank: 2395
- Expression level (log2 read counts): 7.8
Expression Distribution
EZH2 Expression in NALM6 Cells: 7.8
